Active, not recruitingPhase 3NCT05507671

The Role of BCG Vaccine in the Clinical Evolution of COVID-19 and in the Efficacy of Anti-SARS-CoV-2 Vaccines

Studying Severe acute respiratory syndrome

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Oswaldo Cruz Foundation
Principal Investigator
Simone Ladeia-Andrade, MD PhD
Oswaldo Cruz Institute, Oswaldo Cruz Foundation
Intervention
BCG (Bacillus Calmette-Guérin) vaccine(biological)
Enrollment
556 target
Eligibility
18 years · All sexes
Timeline
20212025

Study locations (4)

Collaborators

University of Sao Paulo · Federal University of Juiz de Fora

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05507671 on ClinicalTrials.gov

Other trials for Severe acute respiratory syndrome

Additional recruiting or active studies for the same condition.

See all trials for Severe acute respiratory syndrome

← Back to all trials